Kupando
ID: 16459857Kupando developing TLR 4/7 agonists that stimulate innate immunity for use in oncology and infectious diseases.
1
Funding Rounds
$11.6m
Money raised
Recent Funding Rounds
Overview
Kupando developing TLR 4/7 agonists that stimulate innate immunity for use in oncology and infectious diseases.
- Website:
- Social accounts: linkedin
Unlock Complete Company Intelligence
Access comprehensive data and insights available only to Seedtable members
Financial Details
- • Complete funding history and valuations
- • Revenue estimates and financial metrics
- • Investment round details and terms
People & Contacts
- • Complete leadership team profiles
- • Contact information and email addresses
- • Board members and advisors
Market Intelligence
- • Competitive landscape analysis
- • Market position and growth metrics
- • Industry benchmarking data
Premium Tools
- • Export data and generate reports
- • Save companies to custom watchlists
- • API access for data integration
Join 10,000+ Professionals
Trusted by investors, founders, and analysts worldwide
Access detailed insights on 71,000+ companies worldwide
| Name | Phone | Social networks | |
|---|---|---|---|
| Jo***** Ho****** | - | - |
Funding series
Funding Series Analysis
The company Kupando has raised a total of $11.6m in funding over 1 rounds.
Key Insights:
- Kupando Series A Round, March 2026: $11.6m
Industries
Kupando is active in the following industries: